Comparison of the efficacy of peginterferon alfa-2a + ribavirin and no treatment for the prevention of liver disease in patients with chronic hepatitis C virus infections.

Trial Profile

Comparison of the efficacy of peginterferon alfa-2a + ribavirin and no treatment for the prevention of liver disease in patients with chronic hepatitis C virus infections.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2011

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; Liver dysfunction
  • Focus Therapeutic Use
  • Acronyms LOTOS
  • Most Recent Events

    • 01 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top